cyrilzakka/clinical-trials huggingface dataset:
Detection of Jaundice From Ocular Images Via Deep Learning

Our study presents a detection model predicting a diagnosis of jaundice (clinical jaundice and occult jaundice) trained on prospective cohort data from slit-lamp photos and smartphone photos, demonstrating the model's validity and assisting clinical workers in identifying patient underlying hepatobiliary diseases.

This study demonstrated that deep learning models could detect jaundice using ocular images in blood levels with reasonable accuracy, providing a non-invasive method for jaundice detection and recognition. This algorithm can assist clinical surgeons with daily follow-up visits and provide referral advice. It also highlights the algorithm's potential smartphone application in sizeable real-world population-based disease-detecting or telemedicine programs.

Eligibility Criteria:
Inclusion Criteria:

* The quality of slit-lamp images should be clinical acceptable. More than 90% of the slit-lamp image area, including three central regions (sclera, pupil, and lens) are easy to read and discriminate.

Exclusion Criteria:

* Images with light leakage (\>10% of the area), spots from lens flares or stains, and overexposure were excluded from further analysis
Laparoscopic Splenic Flexure Mobilization

This retrospective cohort study conducted on 140 patients who underwent laparoscopic anterior resection for upper rectal cancer in the period from May 2011 to November 2015, comparison will be done on splenic flexure mobilization excluding .

Presently, it is acknowledged that laparoscopic colectomy for left sided colorectal cancer is the most common surgery operated in laparoscopic colorectal surgeries, However the most debatable question in such type of operations that is it mandatory to do splenic flexure mobilization or not? In the literatures colorectal surgeons divided into 2 teams, those with splenic flexure mobilization in laparoscopic left colorectal resection to have tension free, well vascularized anastomosis On the other hand those against splenic flexure mobilization reported that omitting this step does not significantly affect the leakage rate, morbidity or the oncological outcomes In this study, we evaluate the necessity of splenic flexure mobilization in laparoscopic anterior resection for upper rectal tumors and its impact on the operative time, total morbidity, leakage rate, oncological safety and continence level

Eligibility Criteria:
Inclusion Criteria:

* Patients with upper rectal tumors.

Exclusion Criteria:

* Low and mid rectal cancer
* Splenic flexure tumors, descending colon cancer,
* patients with associated lesions in the right or transverse colon
* Emergency cases.
GEMOX: Oxaliplatin in Pancreatic Cancer

Primary objective:

* To evaluate overall response rate (based on RECIST criterion)

Secondary objective:

* To evaluate time to progression, clinical benefit, quality of life and safety


Eligibility Criteria:
Inclusion Criteria:

* Histologically proven adenocarcinoma of the pancreas
* Metastatic or locally advanced, non resectable disease(Non resectable disease will be determined by the investigators with clinical data)
* Uni-dimensionally measurable disease as defined by RECIST (primary or secondary tumors\>2cm using conventional CT scan or ≥1cm with spiral CT scan)
* No previous chemo or radiotherapy, but postoperative radiotherapy as a adjuvant therapy for non-target lesion is permitted
* Karnofsky Performance Status (KPS) ≥60
* No known Central Nervous System metastases
* No sensory neuropathy at inclusion
* Biological and hematological evaluation \< 2 weeks prior to treatment administration:

  * Neutrophils ≥ 1500/ mm3
  * Platelets ≥ 100,000/mm3
  * Alkaline phosphatases\< 5X ULN(upper Limits of Normal) and Bilirubin \< 1.5X ULN
  * SGOT,SGPT \<2.5 X ULN if no liver metastasis
  * SGOT,SGPT \<5 X ULN if liver metastasis
  * Creatinine \< 1.5 X ULN
* Baseline imaging (CT scan or Magnetic Resonance Imaging) \<3 weeks before treatment administration
* Men and women who are fertile must use a medically acceptable contraceptive throughout the treatment period and for 3 months following cessation of treatment with oxaliplatin. Subjects must be made aware, before entering this trial of the risk of becoming pregnant or in fathering children

Exclusion Criteria:

* Corticotherapy except for anti-emetic purpose
* Pregnant or breast feeding women (Documentation of a negative pregnancy test must be available for premenopausal women with intact reproductive organs)
* Uncontrolled congestive heart failure or angina pectoris, or hypertension or arrhythmia
* Uncontrolled or persistent hypercalcemia
* History of significant neurologic or psychiatric disorders
* Vater ampulomas and biliary tract adenocarcinomas
* Other -non cured- malignancies

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
In-Home Use Study to Evaluate Use of an Intimate Health Product in Females

The purpose of this study is to evaluate the effects of an intimate health product on sexual experience in females.

Study to evaluate consumer perceptions of a cosmetic intimate health product on sexual experience in females, using a validated psychometric questionnaire.

Eligibility Criteria:
Inclusion Criteria:

* Normal, healthy females \>18 years of age
* In committed heterosexual relationship for \>6months
* Of adequate sexual functioning
* On acceptable method of birth control

Exclusion Criteria:

* Pregnant or breastfeeding
* Allergy to product ingredients
* Irritation or infection in genital area
* Unstable or uncontrolled medical condition
Preoperative Measurement of Heart Rate Variability as a Predictor of Postoperative Outcome

The purpose of the study is to confirm the hypothesis that a dysfunction of the autonomic nervous system could complicate the postoperative course in the patient undergoing surgery. Measurement of heart rate variability (HRV) is a non-invasive method for evaluation of the autonomic nervous system.

The autonomic nervous system (ANS) plays an important role in the maintenance of systemic homeostasis. The homeostasis is modified continually by internal and external stimuli to which the autonomic nervous system modulates the response of organism by tight control on essential functions such as circulation, respiration, hormonal secretion and thermoregulation. Dysfunction of the autonomic nervous system could complicate the perioperative course in the patient undergoing surgery; therefore it should be considered as another risk factor during preoperative evaluation. Nowadays the evaluation of the autonomic nervous system function like a tool for prediction postoperative outcome is not considered in daily anaesthesiology practice. Measurement of heart rate variability (HRV) is a method for evaluation the autonomic nervous system function. It is a non-invasive method that provides information about the autonomic regulation of organism and thus it identifies patients with the autonomic nervous system dysfunction.

Eligibility Criteria:
Inclusion Criteria:

* 21 years of age and above
* anticipated duration of surgery more than 120 minutes
* estimated blood loss exceeding more than 15% of blood volume
* American Society of Anesthesiology (ASA) classification 2 or 3

Exclusion Criteria:

* pregnant or lactating women
* age below 21 years of age
* emergency surgery
* American Society of Anesthesiology (ASA) classification 1
* sepsis and septic shock
* severe cardiac arrhythmias
Comparative Study of Autologous Blood Injection Versus Diluted Epinephrine in Treating Actively Bleeding Gastroduodenal Ulcers

Endoscopic injection of autologous blood can control bleeding from gastroduodenal ulcers.

To test the hypothesis that endoscopic injection of autologous blood is superior to endoscopic injection of diluted epinephrine in controlling bleeding from gastroduodenal ulcers.

Eligibility Criteria:
Inclusion Criteria:

* all adult patients with gastroduodenal ulcer

Exclusion Criteria:

* Patients with non ulcer bleeding.
* Patients with malignancy.
* Patients with bleeding disorders or under coagulation therapy.
* Patients with known allergy to epinephrine.
Safety and Efficacy of Paramedic Treatment of Regular Supraventricular Tachycardia

Supraventricular tachycardia (SVT) is a term describing any rhythm coming from the top half of the heart. Although atrial fibrillation is the commonest cardiac arrhythmia, regular SVT's are also common. The two commonest regular SVT's are atrioventricular (nodal) reentry tachycardias (AV(N)RT) and atrial flutter (AFL). Atrioventricular (nodal) reentry tachycardias (AV(N)RT) are common but benign forms of fast heart rhythm. Although AV(N)RT can cause unpleasant symptoms and are frightening it is not dangerous. If patients present with AV(N)RT the accepted and normal treatment for most is to have the fast heart rhythm stopped by either taking a deep breath and straining or by the use of drugs. Patients can then be discharged home and have further investigation and treatment as an outpatient. SVT can be frightening for the patient but is easy to diagnose and treat. There is high success rate post treatment for this benign condition. This is traditionally done in the local accident and emergency, although patients can sometimes be unnecessarily admitted to hospital overnight. We propose to investigate the safety and efficacy of training paramedics to treat safe forms of AV(N)RT at the scene and then giving the patient an information pack which includes a request for a GP referral to a heart rhythm specialist. Patients will be randomly allocated after consenting to take part in the study to either get paramedic or accident and emergency department treatment. We will compare these two approaches by telephone follow up of the patients. The costs of the different approaches will be compared by assessing the rate of appropriate investigation and the information given to patients and how they rated their experiences.


Eligibility Criteria:
Inclusion Patients presenting with regular narrow complex tachycardia on 12 lead ECG

Exclusion Age \< 16 years Already enrolled in the study or another research study Syncope or blackout Sinus tachycardia ECG evidence of myocardial infarction Broad Complex tachycardia A history of illicit drug use within the previous 24 hours A history of structural or ischaemic heart disease Inability or unwillingness to give consent Pregnancy Failure to obtain intravenous access Hypotension - defined as a systolic blood pressure of \<100 systolic Contraindications to Adenosine injection Heart transplant patients Patients on dipyridamole Patients on regular asthma inhalers Obvious atrial flutter
Circulating Factors in Nephrotic Syndrome

A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years
* Plasma albumin \< 36 g/L
* Urine protein \>3.5 g/day or urine protein/creatinine-ratio (UPCR) \> 3.5 or urine albumin/creatinine-ratio (UACR) \>2200 mg/g
* Planned kidney biopsy
* Able to give written informed consent

Exclusion Criteria:

* Kidney transplant recipient
* Previously undergone a kidney biopsy
* Unable to understand written information in Danish
Noninvasive Positive Airway Pressure Ventilation and Risk of Facial Pressure Ulcers

To assess risk of skin pressure lesions in patients treated with noninvasive mechanical ventilation.

Noninvasive ventilation improves the outcome of patients with acute respiratory failure; however patient's discomfort may be responsible for up to a fifth of failures. Scant literature exists on NIV-related pressure ulcers and their determinants.

Aim of the study is to seek for determinants, if any, associated with the development of pressure ulcers related to noninvasive ventilation.

Study design: observational. Patients treated with NIV from December 2009 to December 2011 will be analyzed. Main end-points: to seek for variables associated to the development of NIV-related pressure ulcers in patients with acute respiratory failure.

Eligibility Criteria:
Inclusion Criteria:

* severe dyspnea at rest
* respiratory rate \> 30 per minute
* PaO2/FiO2 \< 200 (despite oxygen with Venturi with a FiO2 og 0.5)
* use of accessory respiratory muscles
* pH \< 7.35 \> 7.10

Exclusion Criteria:

* STEMI
* NSTEMI/Unstable angina
* Hemodynamic instability
* Need for immediate endotracheal intubation
* Inability to protect the airways
* Impaired sensorium
* Pulmonary embolism
* Gastrointestinal bleeding
* Hematological malignancy or neoplasms with ECOG performance status \> 2
Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers

The researchers hypothesize that the impact of increasing systemic exposure to atenolol leads to increased risk for adverse metabolic effects from atenolol therapy in hypertension. This will be accomplished through a 24-hour pharmacokinetic (PK) study and oral glucose tolerance test in hypertensive patients taking chronic atenolol 100 mg daily.

The current study is a sub-study of Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR - NCT00246519). The primary objective of this pharmacokinetic (PK) study is to investigate the correlation of atenolol Cp with hypertriglyceridemia and insulin sensitivity in mild to moderate hypertensive patients after 6-8 weeks of atenolol treatment.

Participants will undergo the PK study when they have been on atenolol 100 mg once daily for at least 4 weeks and on atenolol therapy (50 mg or 100 mg) for ≥ 7 weeks. They will undergo a two hour Oral Glucose Tolerance Test (OGTT), 1 hour after atenolol dosing. Blood will be drawn at 12 time points for 24 hours. Atenolol Cp will be measured in all 12 blood samples and will be correlated with the glucose/insulin measured during the OGTT.

Eligibility Criteria:
Inclusion Criteria:

* Subjects from PEAR who are on atenolol 100 mg once daily will be invited to participate
* Other inclusion criteria from PEAR

Exclusion Criteria:

* Patients with BMI \>35 kg/m2 will be excluded
* Other exclusion criteria from PEAR
Postoperative Lactate and Atrial Fibrillation After CABG

Postoperative atrial fibrillation (POAF) is associated with increased mortality and morbidity in patients undergoing isolated coronary artery bypass grafting (CABG). It has been estimated that 5-40% of CABG patients experience POAF. Advanced age, P wave abnormalities, left atrial dilation, emergency surgery, low left ventricle ejection fraction, low glomerular filtration rate and chronic obstructive pulmonary disease have been reported in the etiology. Predicting which patients would experience POAF following CABG is important since it would allow physicians to apply more focused prophylactic measures. Lactate is the final product of anaerobic glycolysis. Serum lactate level are increased in case of inadequate oxygen delivery to tissues. The investigators aim to assess whether serum lactate levels measured early in the postoperative period could be used as a predictive marker of POAF in adults undergoing isolated CABG.


Eligibility Criteria:
Inclusion Criteria:

* Undergoing isolated CABG
* Age \>18 years

Exclusion Criteria:

* Age \<18 years
* Pregnancy
* History of paroxysmal atrial fibrillation prior to surgery
* Undergoing concomitant procedures (e.g., CABG + valve surgery)
* Any preoperative cardiac rhythm other than normal sinus rhythm
* More than mild cardiac valve stenosis or insufficiency
Thiamine Supplementation in Patients With Septic Shock

To determine if intravenous thiamine would decrease the time to reversal of shock in patients with septic shock.

Patients will be randomized to thiamine supplementation or placebo in a 1:1 ratio. Randomization will be done by the hospital pharmacy department whom will be the only unblinded participants. Patients will receive 200mg thiamine in 50mL of 5% dextrose or matching placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit. The drug will be mixed by the pharmacy. Administration will be done in the patients room in the intensive care unit by the patient's assigned nurse. Blood will be collected on admission to the hospital in order to determine baseline lactate level and study eligibility. The measurement of lactate is standard of care in patients with sepsis. Thiamine level will be collected upon enrollment into the study. The ICU nurse or emergency room nurse taking care of the patient at the time of enrollment will draw the blood sample. Standard procedure for measuring thiamine levels will be maintained including protecting the blood sample from light and keeping it on ice while it is delivered to the lab. Serum lactate will be measured daily for 7 days or until discharge from the intensive care unit. The serial measurement of serum lactate is considered standard of care in patients with sepsis.

Eligibility Criteria:
Inclusion Criteria:

* Age\>18
* Sepsis (defined as presence of two or more SIRS criteria with documented or suspected infection)
* SIRS: Systemic Inflammatory Response Syndrome (SIRS) is the occurrence of at least two of the following criteria: temperature \>38.0ºC or \<36.0ºC, heart rate \>90 beats/minute, respiratory rate \>20 breaths/minute, white blood cell count \>12,000 or \<4000.
* Lactate \>3mmol/L at the time of consent and randomization
* Hypotension (systolic blood pressure \<90mmHg) after a \>2L fluid bolus
* Vasopressor dependence (defined as the continuous infusion of norepinephrine, dopamine, phenylephrine, vasopressin or epinephrine.)

Exclusion Criteria:

* Known cirrhosis or chronic liver disease
* Current thiamine supplementation
* Clinical indication for thiamine (e.g. Alcohol abuse)
* Comfort measures only designation
* Inability to provide consent
* Other causes for lactate elevation (seizure, use of medications that can cause lactic acidosis such as metformin, linezolid and anti-retrovirals, carbon monoxide, known or suspected bowel or limb ischemia, cardiac arrest prior to enrollment)
A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer

This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥18 years, male or infertile female
* Patients with rectal adenocarcinoma diagnosed by colonoscopic biopsy
* Neoadjuvant therapy according to guideline recommendations
* Endoscopic biopsy with access to biopsy tissue for subsequent RNA-seq testing
* Patients who do not have a combination of primary malignant tumors elsewhere.
* Patients who understand the purpose of the trial, participate voluntarily and sign an informed consent form.

Exclusion Criteria:

* Samples are not collected, stored, or processed in accordance with specified requirements
* Sample does not meet the requirements for subsequent RNA-seq testing
* Cases enrolled with a subsequent diagnosis other than rectal adenocarcinoma.
* The patient refuses or is unable to complete the entire neoadjuvant treatment
* Lack of post-neoadjuvant imaging results and lack of routine postoperative pathology results.
* Other patients who, in the judgment of the investigator, do not meet the enrollment requirements
Accuracy Comparison of Two CGMs in Hospitalized Patients

The purpose of the study is to determine the accuracy of two different continuous blood sugar monitoring systems in hospitalized patients by comparing them standard laboratory blood sugar testing in the hospital.


Eligibility Criteria:
Inclusion Criteria:

1. All genders, admitted to UC San Diego Hillcrest Medical Center with an anticipated remaining length of stay of ≥24 hours
2. Age ≥18 years at the time of consent
3. Requiring standard of care intravenous insulin infusion therapy at the time of consent with an anticipated duration of intravenous insulin infusion ≥12 hours
4. Willingness to provide informed consent and follow all study procedures

Exclusion Criteria:

1. Current bleeding disorder, treatment with anticoagulants, or platelet count below 50,000/mL at enrollment
2. Lack of appropriate sites for sensor placement (sites must be free of scars, skin irritation, surgical wounds, dressings, etc.)
3. Planned magnetic resonance imaging (MRI) study within 24 hours of enrollment
4. Any other condition that, based on Investigator's judgment, would jeopardize patient safety during trial participation or would affect the study outcome
Enhancing Psychological Skills and Well-being in Sport Through a Blended Intervention: a Controlled Study With Perform-UP Tennis

Mental preparation is a fundamental aspect of athletic performance. The investigators present here an experiment aimed at evaluating the effectiveness of a blended intervention to promote mindfulness and self-confidence and a reduction of anxiety among professional athletes. Perform-UP Tennis is an application that provides a weekly mental training program to be integrated into the athlete's daily routine. The intervention included eight weekly modules with variable and progressive training and relaxation exercises. Meetings with the athletes took place every 2 weeks. The study involved 41 tennis players who were randomly assigned to either the intervention or the control group.


Eligibility Criteria:
Inclusion Criteria:

* being tennis players with a minimum age of 14
* being fluent in Italian
* having a smartphone with an Internet connection

Exclusion Criteria:

* having hearing difficulties
* not playing tennis
* being younger than 14 years old
* not having a good knowledge of Italian
Usefulness of Shirodhara for Insomnia

This pilot study will attempt to test the effects of this non-invasive procedure on a small sample of insomnia patients and also determine the feasibility of recruiting and retaining participants during the trial for such treatments in the United States.

A prospective case series design will be adopted. Due to the small sample size and the preliminary nature of the study, a single case study or case series are classified under Observational Descriptive Studies. The investigators will seek local Institutional Review Board (IRB) approval. Ten volunteers who respond to the recruitment efforts will be enrolled into the study. Successful enrollment is based on strict inclusion and exclusion criteria. Brahmi oil (sesame oil processed with Bacopa monieri and other herbs) will be used to perform Shirodhara. Each participant will be treated for 40 minutes for five consecutive days. Outcome measures data will be collected at baseline, third day and fifth day and a week after the treatment is over. Additionally, demographic data will be collected at baseline as well. Participants will be asked to record any adverse events or side effects they observe during the study period.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-75 of either sex
* Duration of insomnia at least one year
* Willing to sign an informed consent
* A score of minimum 14 on the Insomnia severity index

Exclusion Criteria:

* Comorbidities such as Depression or any other psychological conditions that require medications
* Currently on prescription medication for insomnia
* Serious medical conditions such as uncontrolled hypertension, uncontrolled diabetes, or any other acute condition that disturbs sleep and requires waking up in the middle of the night
* Participants unwilling to comply with the protocol
* Anyone who is in litigation or receiving disability, workers' compensation benefits